Literature DB >> 32827084

T2 Peptide Represents a Major Autoantigen Epitope in Experimental Autoimmune Prostatitis.

Yuqian Liu1, Meng Tang1, Qin Zhang1, Cuican Li1, Rundong Lv1, Hanhui Min1, Xiaohui Zhou2,3,4.   

Abstract

Chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS) is a clinical tricky problem due to its enigmatic etiology, low cure rate, and high recurrence rate. The research on its pathogenesis has never stopped. In this experimental autoimmune prostatitis (EAP) model, male C57BL/6 mice were subcutaneously immunized with prostate extracts in an adequate adjuvant. For mice in the antibody intervention group, anti-T2 polyclonal antibodies were intraperitoneally injected during the induction of EAP. Animals were periodically monitored for pelvic pain. Hematoxylin and eosin staining was used to assess prostate inflammation. Tumor necrosis factor-α (TNF-α) levels in serum were measured by ELISA kits. The immunized animals developed prostatitis as a consequence of the immune response against prostate antigens. Pelvic pain thresholds were gradually decreased and TNF-α expression significantly increased. T2 plays an important role in the disease since polyclonal antibodies to T2 greatly ameliorated symptoms in animals induced for EAP. T2 peptide may represent the major autoantigen epitope in EAP, which could serve for a better understanding of the etiology of CP/CPPS.

Entities:  

Keywords:  Autoantigen epitope; Autoimmune disease; Chronic prostatitis/chronic pelvic pain syndrome; T2 peptide

Year:  2020        PMID: 32827084     DOI: 10.1007/s10753-020-01326-6

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  20 in total

Review 1.  Urologic chronic pelvic pain syndrome: insights from the MAPP Research Network.

Authors:  J Quentin Clemens; Chris Mullins; A Lenore Ackerman; Tamara Bavendam; Adrie van Bokhoven; Benjamin M Ellingson; Steven E Harte; Jason J Kutch; H Henry Lai; Katherine T Martucci; Robert Moldwin; Bruce D Naliboff; Michel A Pontari; Siobhan Sutcliffe; J Richard Landis
Journal:  Nat Rev Urol       Date:  2019-03       Impact factor: 14.432

Review 2.  Chronic pelvic pain syndrome: a clinical enigma.

Authors:  Avi Stein; Tal May; Yoram Dekel
Journal:  Postgrad Med       Date:  2014-07       Impact factor: 3.840

3.  Brain functional and anatomical changes in chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Melissa A Farmer; Mona L Chanda; Elle L Parks; Marwan N Baliki; A Vania Apkarian; Anthony J Schaeffer
Journal:  J Urol       Date:  2011-05-14       Impact factor: 7.450

4.  Comorbid clinical conditions in chronic fatigue: a co-twin control study.

Authors:  L A Aaron; R Herrell; S Ashton; M Belcourt; K Schmaling; J Goldberg; D Buchwald
Journal:  J Gen Intern Med       Date:  2001-01       Impact factor: 5.128

5.  A novel mouse model of chronic prostatitis/chronic pelvic pain syndrome induced by immunization of special peptide fragment with aluminum hydroxide adjuvant.

Authors:  Farhan Ullah Khan; Awais Ullah Ihsan; Waqas Nawaz; Muhammad Zahid Khan; Mengqi Yang; Gang Wang; Xiaoqian Liao; Lei Han; Xiaohui Zhou
Journal:  Immunol Lett       Date:  2017-05-16       Impact factor: 3.685

6.  Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS).

Authors:  G R D Batstone; A Doble; J S H Gaston
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

Review 7.  Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy.

Authors:  A S Polackwich; D A Shoskes
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-03-08       Impact factor: 5.554

8.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

9.  Chronic prostatitis/chronic pelvic pain syndrome in males may be an autoimmune disease, potentially responsive to corticosteroid therapy.

Authors:  I Tomaskovic; B Ruzic; D Trnski; O Kraus
Journal:  Med Hypotheses       Date:  2008-12-17       Impact factor: 1.538

10.  Anti‑IL‑39 (IL‑23p19/Ebi3) polyclonal antibodies ameliorate autoimmune symptoms in lupus‑like mice.

Authors:  Xiaoqian Wang; Yu Zhang; Zhiding Wang; Xiaoling Liu; Gaizhi Zhu; Gencheng Han; Guojiang Chen; Chunmei Hou; Tianxiao Wang; Beifen Shen; Yan Li; He Xiao; Ning Ma; Renxi Wang
Journal:  Mol Med Rep       Date:  2017-11-14       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.